DRKS00016066已完成3 期
Early Palliative Care for Patients with Glioblastoma; a randomized phase lll clinical trial - EPCOG
niversität zu Köln0 个研究点目标入组 231 人开始时间: 2019年4月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 231
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients with newly diagnosed Glioblastoma (histologically confirmed by biopsy or resection) within 4 weeks of diagnosis
- •-Patients with recurrent Glioblastoma within 4 weeks after diagnosis of relapse
- •-Eastern Cooperative Oncology Group (ECOG) Scale: 0-2
- •-Age = 18 years
- •-ability to understand, read and respond to the German language
- •-ability to give written consent
- •-Person (relative or other closely acquainted person) of particular importance to the patient, i.e. living together or in personal contact with the patient at least twice a week. (Caution: Patients may also be included if such a person does not exist.)
- •-Eastern Cooperative Oncology Group (ECOG) Scale: 0-2
- •-Age = 18 years
- •-ability to understand, read and respond to the German language
- •-ability to give written consent
排除标准
- •Patients and relatives:
- •-Refusal to adhere to the study protocol
- •-legal incapacity
- •-prolonged use of drugs or alcohol or psychiatric disease which, in the opinion of the investigator, makes the patient or relative unsuitable for participation in the study
- •-Any dependence on the investigators or employed by the sponsor or investigator.
- •-legal or official placement in an institution
研究者
相似试验
已完成
不适用
Early Palliative Care for patients with symptomatic Heart FailureI50.12I50.13I50.14DRKS00013922niklinik BonnMedizinische Klinik II206
已完成
1 期
Early specialty palliative care for patients with advanced lung cancer undergoing chemotherapy: Feasbility studyAdvanced Lung CancerJPRN-UMIN000012772ational Cancer Center Hospital East50
进行中（未招募）
1 期
Study to evaluate the potentiation effect of radiotherapy by AGuIX nanoparticles for the treatment of persistent glioblastomaPersistent Glioblastoma Multiforme, grade IVMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003774-32-ITDIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA30
进行中（未招募）
不适用
First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study. - NAGlioblastoma MultiformeEUCTR2009-013406-13-CZMasaryk University
进行中（未招募）
不适用
First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells - GBM-VaxPatients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiation therapy and standard chemotherapy with temozolomide.MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015979-27-ATActivartis Biotech GmbH76